Objective

• Biologics, such as monoclonal antibodies, recombinant proteins, and nucleic acid therapies, have become essential in drug discovery due to their precise targeting, enhancing therapeutic efficacy and reducing side effects in treating complex diseases. Despite these advantages, their development is challenging, often involving complex, costly production, stability issues, and stringent regulatory requirements, therefore, there is a critical need for alternative therapeutic approaches within specific domains.
• To address these challenges, our internal strategy focuses on developing a small molecule inhibitor that targets a therapeutically validated pathway, providing a viable alternative to overcome the limitations associated with current biologics.

Methodology

• Our methodology involves using our proprietary AI/ML model (RxAgentAI ) to formulate a small molecule inhibitor by identifying the protein structure and its druggable pocket for the target of interest.
• This process entails a detailed analysis of the structural and topological principles that regulate protein functionality, which helps in the subsequent design and synthesis of the compounds.
• Leveraging our team of distinguished scientists, medicinal chemists, computational biologists, and our proprietary technological assets, we engineer small molecule targeting a range of receptors.
• These compounds are then evaluated through functional screening assays.

Outcomes / Impact

Small molecules offer several advantages over biologics, including easier oral administration, lower production costs, and the ability to penetrate cell membranes for broader tissue distribution. They are typically more stable, with simpler storage requirements and longer shelf lives. Additionally, small molecules are less likely to provoke immune responses and have more scalable production processes, making them more accessible for widespread use.